Search Videos and More
Document
Tip Sheet: Laboratory Monitoring for Patients on Oral Chemotherapy or Oral Targeted Therapies
The Breast Oncology Center developed this reference for providers on lab monitoring for patients on oral chemotherapy or oral targeted therapies in November 2025.
Course
3rd Annual Lynch Syndrome Scientific Symposium
The 3rd Annual Lynch Syndrome Scientific Symposium will be held on Monday, April 13 at Hotel Commonwealth in Boston, MA. This symposium is dedicated to researchers and clinicians focused on the study and clinical care of individuals with Lynch syndrome. We will be accepting abstracts on Lynch syndrome research and relevant case reports. The deadline to submit an abstract is February 16, 2026 at 11:59PM EST.
News
Dana-Farber Research News 01.15.2026
This twice-monthly newsletter highlights recently published research where Dana-Farber faculty are listed as first or senior authors. The information is pulled from PubMed and this issue notes papers published from December 16 - 31.
Symposium
Breast Cancer Breakthroughs: SABCS 2025 Highlights
Experts in Dana-Farber’s Breast Oncology Center discuss highlights in breast cancer research innovation presented at SABCS 2025 in San Antonio, Texas providing state-of-the-art information on experimental biology, etiology, prevention, diagnosis, and therapy of breast cancer and premalignant breast disease.
Symposium
Breast Cancer Breakthroughs: ESMO 2025 Highlights
Experts in Dana-Farber’s Breast Oncology Center discuss highlights in breast cancer research innovation presented at ESMO25 in Berlin, Germany, including what the data mean, how it can be used in clinic, and what’s next in the field of breast cancer research.
News
Dana-Farber Research News 01.01.2026
This twice-monthly newsletter highlights recently published research where Dana-Farber faculty are listed as first or senior authors. The information is pulled from PubMed and this issue notes papers published from December 1 - 15.
Video
Jorge J. Castillo, MD discusses results from a multicenter phase 2 Study
High VGPR/CR rates with pirtobrutinib plus venetoclax in previously treated Waldenstrom macroglobulinemia
Video
Andrew A. Lane, MD, PhD discuss results from a phase 2 Study
Tagraxofusp, azacitidine, and venetoclax (TAG-AZA-VEN) triplet therapy shows efficacy, tolerability, and transplant potential in patients with blastic plasmacytoid dendtritic cell neoplasm (BPDCN)
Video
Reid W. Merryman, MD discusses results of a multicenter phase II trial
Rituximab and epcoritamab as first-line therapy for patients with high-tumor burden follicular lymphoma
Video
Omar Nadeem, MD discusses results of the Phase II d-PRISM study
Daratumumab in high-rish MGUS and low-risk smoldering myeloma
Video
Mahasweta Gooptu, MD discusses results from the NMDP-sponsored access expansion Study
Phase 2 Study of post transplant cyclophosphamide-based graft versus host disease prophlaxis after HLA-mismatched unrelated donor transplantation and reduced intensity conditioning
Video
Jacqueline Garcia, MD discussed results from the Phase # VERONA study
Subgroup analyses from the randomized, Phase 3 VERONA study of venetoclax with azacitidine (Ven+Aza) versus placebo with azacititine (Pbo+Aza) in patients with treatment-naive, intermediate and higher-risk Myelodysplastic Syndromes (HR-MDS)